POSTER SESSION IV
Tuesday, March 1, 2011 — 1:00 PM - 4:30 PM
Exhibit Hall
Click on the blue numbers in parentheses to display abstracts.
Click the button next to any title to add to Itinerary Planner...
ENDOCRINE PATHOLOGY
Poster#
Title and Authors
Itinerary Planner
32
Trends in Thyroid Pathology. Steady Prevalence of PTC and Rise of Nodular Goiter in Thyroidectomies.
(581)
S Lino-Silva, E Medina-Lopez, D Acuna-Gonzalez, O Gonzalez-Trevino, A Gamboa-Dominguez - INCMN Salvador Zubiran, Mexico City, DF, Mexico
An Analysis of the Revised CAP Protocol for Reporting Papillary Thyroid Carcinoma (PTC).
(585)
MB McCready, H Mani, N Williams, HS Crist - PSHMC, Hershey, PA
Immunohistochemical Subclassification of Thyroid Tumor with Prominent Hyalinizing Trabecular Pattern.
(579)
S Lee, JS Koo, SW Hong - Yonsei University College of Medicine, Seoul, Korea
Claudin-1 and -7 Expression in Solid Cell Nests of the Thyroid: An Enigmatic Analogy with Papillary Carcinoma.
(565)
C Colato, A Fierabracci, A Dardano, F Monzani, M Chilosi, G Martignoni, F Menestrina, M Ferdeghini - University of Verona, Italy; Children's Hospital Bambino Gesu, IRCCS, Rome, Italy; University of Pisa, Italy
AQP4 and Histone H1.5 Immunostaining Can Distinguish Benign Oncocytic Follicular Lesions from Oncocytic Follicular Carcinoma.
(563)
J Chepovetsky, DE Burstein, E Genden, M Rivera - Mount Sinai Medical Center, NYC, NY
CDX2 Is Rarely Expressed in Columnar Cell Variant of Papillary Thyroid Carcinoma: A Study of Ten Cases.
(593)
V Sujoy, A Pinto, CM Kovacs, V Nose - Jackson Memorial Hospital/University of Miami, Miami, FL
Cyclin D1 Expression in Benign and Malignant Differentiated Tumors of the Thyroid Gland.
(592)
TP Seybt (1), P Ramalingam, J Huang (2), SW Looney (2), MD Reid - Georgia Health Sciences University, Augusta; Emory University Hospital, Atlanta, GA
Morphoproteomics Demonstrates Activation of mTORC2 in Aggressive Histologic Variants of Papillary Thyroid Carcinoma.
(583)
J Liu, RE Brown - University of Texas Health Science Center at Houston Medical School
Potential Role of MAPK Inhibitor in the Benzo(a)pyrene-Induced Anti-Apoptosis Against Cisplatin Treatment and Tumor Tumor Invasion of Papillary Thyroid Carcinoma Cells.
(562)
YS Chae, K-S Ahn, H Kim, NH Won - Korea University College of Medicine, Seoul, Korea
Expression of Adenosine Receptors in Thyroid Carcinoma.
(574)
T Kondo, T Nakazawa, T Kawasaki, K Mochizuki, D-F Niu, T Yamane, R Katoh - University of Yamanashi, Chuo, Japan
Relationship of Mitogen-Activated Protein Kinase and Stromal Reaction in Sporadic Thyroid Malignancies: Role of MAP3K8 in Papillary Carcinomas.
(586)
J Moorhead, R Lam, L Lam, A Blanes, SJ Diaz-Cano - King's College Hospital, London, United Kingdom; University of Malaga School of Medicine, Spain
Should Reflexive BRAF Testing Be Performed on Atypical/Borderline Thyroid Nodules?
(584)
JD Marotti, JA Lefferts, VA Memoli, AC Golding, GJ Tsongalis, V Padmanabhan - Dartmouth-Hitchcock Medical Center, Lebanon, NH
A Genome-Wide Screening of Promoter DNA Methylation Reveals Differential Profiles of Follicular-Cell Derived Thyroid Neoplasms.
(575)
T Kondo, T Nakazawa, T Kawasaki, K Mochizuki, D-F Niu, T Yamane, R Katoh - University of Yamanashi, Chuo, Japan
The Use of Immunohistochemical Expression of SF-1 and EMA in Distinguishing Adrenocortical Tumors from Renal Neoplasms.
(567)
ML Enriquez, P Lal, A Ziober, L Wang, JE Tomaszewski, Z Bing - Hospital of the University of Pennsylvania, Philadelphia
Cell Survival in MEN2 Thyroid and Adrenal Medullary Neoplasms: Role of PI3 Kinase/AKT Pathways.
(573)
T Ioannidis, R Lam, L Lam, A Blanes, SJ Diaz-Cano - King's College Hospital, London, United Kingdom; University of Malaga School of Medicine, Spain
TRAP-1 Is a New Surrogate Marker for SDH Mutation in Pheochromocytoma/Paraganglioma and a Potential Target for Chemotherapy.
(590)
JF Powers, SM Fliedner, I Leav, DC Altieri, K Pacak, AS Tischler - Tufts Medical Center, Boston, MA; NIH/NICHD, Bethesda, MD; University of Massachusetts Medical Center, Worcester; Wistar Institute, Philadelphia, PA
Paradoxal Loss of PDGF-CC Expression in Pheochromocytomas and Paragangliomas.
(589)
A Pinto, V Sujoy, U Eriksson, M Neville, V Nose - Jackson Memorial Hospial/University of Miami, Miami, FL; Ludwig Institute for Cancer Research, Karolinska Institute, Stockholm, Sweden
Evaluation of SDHB Immunohistochemistry in the Evaluation of Pheochromocytomas and Paragangliomas from Patients with and without Succinate Dehydrogenase B (SDHB) Mutations.
(569)
L Fishbein, K Nathanson, VA LiVolsi, PJ Zhang, KT Montone - University of Pennsylvania, Philadelphia
Expression of an Activated Mammalian Target of Rapamycin (mTOR) in Gastroenteropancreatic Neuroendocrine Tumors (GEPNETs).
(566)
D Dhall, S Bose - Cedars-Sinai Medical Center, Los Angeles
Immunohistochmical Detection of SSTR2a in Gastro-Entero-Pancreatic Neuroendocrine Tumors (GEPNET) and Response to Somatostatin Analogue (SA).
(588)
RY Osamura, H Hirabayashi, M Matsuda, T Itoh - IUHW Mita Hospital, Minato-ku, Tokyo, Japan
Serotonin-Producing EC-Cell Tumors of the Pancreas. Morphological, Immunohistochemical, Ultrastructural and FISH Study of 15 Cases and Comparison with Intestinal EC-Cell Tumors.
(578)
S La Rosa, A Perren, A Schmitt, L Albarello, B Bernasconi, G Finzi, C Capella - Ospedale di Circolo, Varese, Italy; University of Berne, Switzerland; San Raffaele Scientific Insitute, Milan, Italy; University of Insubria, Varese, Italy
Biomarker Expression in Pancreatic Endocrine Tumors.
(556)
LJ Adhikari, JA Gilbert, RV Lloyd, MM Ames - Mayo Clinic, Rochester, MN; University of Wisconsin School of Medicine, Madison
Heat Shock Protein 90 (HSP90) Expression in Pancreatic Endocrine Neoplasms: A Potential Therapeutic Target and Predictor of Behavior.
(571)
AA Gonzalez-Longoria, H Remotti - Columbia University Medical Center, New York, NY
FGFR3 Transcript and Protein Down-Regulation Is a Negative Prognostic Factor and Correlates with Promoter Methylation in Pancreatic Islet Cell Tumors.
(587)
M Nassiri, S Ramos, M Jorda - Indiana University School of Medicine, Indianapolis; Univerisity of Miami, FL
Comparison of an Expanded Immunohistochemical Panel To Distinguish High Grade Non-Merkel Cell Neuroendocrine Carcinomas from Merkel Cell Carcinoma.
(568)
A Faustin, C Annaiah, D Dhall, B Balzer - Cedars Sinai Medical Center, Los Angeles, CA
button next to any title to add to Itinerary Planner...
Add
